| Probing Prefrontal Cortex Hemodynamic Alterations for Major Depression Disorder (NCT03595020) | Xijing Hospital | 2017-02-16 |
| Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder (NCT03002077) | Naurex, Inc, an affiliate of Allergan plc | 2017-02-03 |
| NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits (NCT02994433) | Washington University School of Medicine | 2017-01-27 |
| Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression (NCT03027362) | Yale University | 2017-01-01 |
| Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies (NCT03283670) | Washington University School of Medicine | 2016-11-22 |
| A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder (NCT02951988) | Naurex, Inc, an affiliate of Allergan plc | 2016-11-13 |
| Gaze Contingent Feedback in Major Depressive Disorder (MDD) (NCT02945735) | Tel Aviv University | 2016-11-06 |
| A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03) (NCT02943577) | Naurex, Inc, an affiliate of Allergan plc | 2016-11-02 |
| Can the Memory Support Intervention Improve Depression Outcome Following Cognitive Therapy? (NCT02938559) | University of California, Berkeley | 2016-11-01 |
| A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02) (NCT02943564) | Naurex, Inc, an affiliate of Allergan plc | 2016-11-01 |
| Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD) (NCT03014544) | Janssen Research & Development, LLC | 2016-10-26 |
| A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder (NCT02902601) | Janssen Research & Development, LLC | 2016-10-17 |
| A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01) (NCT02932943) | Naurex, Inc, an affiliate of Allergan plc | 2016-10-15 |
| A 7-year Assessment on Subject Understanding of ZYBAN/ WELLBUTRIN Associated Risks (NCT03001440) | GlaxoSmithKline | 2016-10-07 |
| The Effects of tDCS on Depressive Symptoms,Neurocognitive Function and HRV in Unipolar Depression and Bipolar Depression (NCT03287037) | Tri-Service General Hospital (TSGH) | 2016-10-01 |
| Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder (NCT02919501) | H. Lundbeck A/S | 2016-09-27 |
| Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age (NCT02871297) | H. Lundbeck A/S | 2016-08-17 |
| Stimulation of Parieto-hippocampal Connectivity in Patients With Major Depressive Disorder (NCT04081519) | University Hospital, Bonn | 2016-08-02 |
| Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness (NCT02845440) | Massachusetts General Hospital | 2016-07-14 |
| A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers (NCT02698553) | GlaxoSmithKline | 2016-05-23 |
| Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD) (NCT02709655) | H. Lundbeck A/S | 2016-05-18 |
| Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD) (NCT02709746) | H. Lundbeck A/S | 2016-05-01 |
| Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder (NCT04013464) | Peking University Sixth Hospital | 2016-05-01 |
| Chronobiology, Sleep Related Risk Factors and Light Therapy in Perinatal Depression: the Life-ON Project (NCT02664467) | Ospedale Regionale di Lugano | 2016-05-01 |
| Brain Derived Neurotropic Factor Response to Aerobic Exercise Intensity in Depressive Patients. (NCT02741622) | St. Olavs Hospital | 2016-03-01 |
| NMDA Modulation in Major Depressive Disorder in Late- Life (NCT03414931) | Chang Gung Memorial Hospital | 2016-01-01 |
| Depression and Immune Function in Multiple Sclerosis (MS) (NCT02740296) | Charite University, Berlin, Germany | 2015-11-01 |
| Clinical and Suicidal Features of Urban, Turkish Middle Age Depressive Patients With Comorbid ADHD (NCT03721588) | Bozyaka Training and Research Hospital | 2015-09-01 |
| Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) (NCT02452892) | Tal Medical, Inc. | 2015-09-01 |
| An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder (NCT02473289) | Janssen Research & Development, LLC | 2015-07-23 |
| Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder (NCT02466477) | Assurex Health Inc. | 2015-06-01 |
| Peripheral Immunomarker Validation in Treatment-resistant Depression (NCT02752178) | University of Cambridge | 2015-06-01 |
| NeuroQore rTMS (Monophasic vs. Biphasic) for Major Depressive Disorder: A Randomized Controlled Pilot Trial (NCT02667041) | University of Ottawa | 2015-05-01 |
| Adolescent Mental Health: Canadian Psychiatric Risk and Outcome Study (NCT02739932) | University of Calgary | 2015-03-01 |
| A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise (NCT02407704) | Kirk Erickson, PhD | 2015-03-01 |
| E-Compared-CH: Comparative Effectiveness Research on Internet-based Depression Treatment - Swiss Trial (NCT02410616) | University of Bern | 2015-03-01 |
| The Effect of Traumatic Childbirth on the Incidence of PTSD and Other Major Postpartum Psychopathology (NCT02370576) | Rambam Health Care Campus | 2015-03-01 |
| Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder (NCT02191397) | GlaxoSmithKline | 2015-02-10 |
| Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder (NCT02659085) | Pouya Movahed Rad | 2015-02-01 |
| Combining Data Sources to Identify Effect Moderation for Personalized Mental Health (NCT05267873) | Johns Hopkins Bloomberg School of Public Health | 2015-01-01 |
| Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD) (NCT02489305) | Janssen Research & Development, LLC | 2014-12-15 |
| A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder (NCT02288325) | Forest Laboratories | 2014-11-18 |
| Confirmation Bias Towards Treatments of Depressive Disorders in Social Tagging (NCT03899168) | Leibniz-Institut für Wissensmedien | 2014-11-14 |
| Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression (NCT04469322) | San Diego Veterans Healthcare System | 2014-09-30 |
| Ketamine Infusions for Major Depression Disorder (NCT02219867) | Sheba Medical Center | 2014-08-01 |
| Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients (NCT02529462) | AB Biotics, SA | 2014-07-01 |
| Dialogue to Empower Traditional and Faith Healers to Deliver mhGAP-IG Adapted Psychosocial Interventions in Kenya (NCT03165513) | Africa Institute of Mental and Brain Health (AFRIMEB) | 2014-07-01 |
| Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress (NCT02196506) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2014-07-01 |
| OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females (NCT02116361) | Allergan | 2014-04-22 |
| A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom (NCT01870843) | Xian-Janssen Pharmaceutical Ltd. | 2014-03-01 |
| A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants (NCT02067299) | Janssen Research & Development, LLC | 2014-02-01 |
| A Randomized Controlled Trial of PCIT-ED for Preschool Depression (NCT02076425) | Washington University School of Medicine | 2014-01-13 |
| The Activation on Prefrontal Cortex With Acupuncture and Moxibustion for Major Depressive Disorder: A Study of Functional Near Infrared Spectroscopy (NCT04272476) | Chengdu University of Traditional Chinese Medicine | 2014-01-01 |
| Objective Diagnostic Markers and Personalized Intervention in MDD Patients (NCT02023567) | Peking University | 2013-11-01 |
| PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011 (NCT02039960) | GlaxoSmithKline | 2013-11-01 |
| A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS) (NCT01909232) | Cervel Neurotech, Inc. | 2013-07-01 |
| A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial (NCT01727726) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2012-12-01 |
| Mommy-Baby Treatment for Perinatal Depression (NCT01744041) | Washington University School of Medicine | 2012-11-01 |
| Cortical Excitability and Inhibition in MDD (NCT01718730) | Mayo Clinic | 2012-10-01 |
| Whole Body Hyperthermia and Major Depression (MDD) (NCT01625546) | University of Arizona | 2012-07-01 |
| Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder (NCT01564862) | Takeda | 2012-04-01 |
| Brain Imaging, Genetics and Treatment for Major Depression (NCT01568684) | National Institute of Mental Health (NIMH) | 2012-03-12 |
| Characterization of the Prosocial and Prosexual Effects of GHB (NCT02342366) | University of Zurich | 2012-02-01 |
| A Study to Evaluate the Effect of Genotype on LY2216684 (NCT01460381) | Eli Lilly and Company | 2011-10-01 |
| Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) (NCT01360866) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2011-10-01 |
| Buprenorphine for Treatment Resistant Depression (NCT01407575) | University of Pittsburgh | 2011-09-01 |
| Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial (NCT01583400) | Dartmouth-Hitchcock Medical Center | 2011-09-01 |
| A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects (NCT01389752) | Eli Lilly and Company | 2011-07-01 |
| Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial) (NCT01360645) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2011-07-01 |
| A Study to Evaluate the Effect of Food on LY2216684 (NCT01389765) | Eli Lilly and Company | 2011-07-01 |
| Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) (NCT01360632) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2011-06-01 |
| A Study of LY2216684 in Healthy Females (NCT01373931) | Eli Lilly and Company | 2011-06-01 |
| European Deep Brain Stimulation (DBS) Depression Study (NCT01331330) | Abbott Medical Devices | 2011-05-01 |
| Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD) (NCT01284218) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2011-01-01 |
| Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder (NCT01255787) | Takeda | 2010-11-01 |
| Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features (NCT01477931) | Chi-Un Pae | 2010-11-01 |
| A Study of LY2216684 in Participants With Impaired Hepatic Function (NCT01241435) | Eli Lilly and Company | 2010-10-01 |
| A Safety Study in Participants With Major Depressive Disorder (NCT01155661) | Eli Lilly and Company | 2010-10-01 |
| Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study (NCT01152996) | Takeda | 2010-09-01 |
| Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder (NCT01179516) | Takeda | 2010-08-01 |
| Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder (NCT01163266) | Takeda | 2010-07-01 |
| A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD) (NCT01138007) | GlaxoSmithKline | 2010-06-17 |
| Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder (NCT01153009) | Takeda | 2010-06-01 |
| Efficacy Study of Transcranial Direct Current Stimulation to Treat Major Depressive Disorder (NCT01033084) | University of Sao Paulo | 2009-12-01 |
| An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms (NCT01814098) | Xian-Janssen Pharmaceutical Ltd. | 2009-07-07 |
| Insulin Resistance in Patients With Major Depression (NCT01106313) | Stanford University | 2009-07-01 |
| GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression (NCT00931619) | National Institute of Neurological Disorders and Stroke (NINDS) | 2009-06-29 |
| The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use (NCT01141400) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2009-06-01 |
| Outcomes in MEasurement-Based Treatment (NCT01141387) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2009-05-01 |
| Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder (NCT00892463) | Sunnybrook Health Sciences Centre | 2009-05-01 |
| A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder (NCT00880399) | GlaxoSmithKline | 2009-03-01 |
| Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder (NCT00824291) | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-02-01 |
| Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder (NCT00844194) | Boehringer Ingelheim | 2009-02-01 |
| A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder (NCT00840034) | Eli Lilly and Company | 2009-02-01 |
| A Study in Adult Patients With Major Depressive Disorder (NCT00795821) | Eli Lilly and Company | 2008-12-01 |
| A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder (NCT00733980) | GlaxoSmithKline | 2008-10-02 |
| Psychiatric Genotype/Phenotype Project Repository (NCT00762866) | Vanderbilt University | 2008-09-01 |
| Switching to Duloxetine in Patients With Depression (NCT00696774) | Eli Lilly and Company | 2008-06-01 |
| A Study of Transcranial Direct Current Stimulation (tDCS) to Treat Depression (NCT00763230) | The University of New South Wales | 2008-04-01 |
| Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome (NCT00671515) | Joseph Calabrese, MD | 2008-04-01 |